Headlines about Quest Diagnostics (NYSE:DGX) have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Quest Diagnostics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 45.3792252886134 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media headlines that may have effected Accern’s rankings:
- Quest Diagnostics Inc (DGX) Expected to Post Earnings of $1.54 Per Share (americanbankingnews.com)
- Analyzing TeamHealth (TMH) and Quest Diagnostics (DGX) (americanbankingnews.com)
- Quest Diagnostics Long-Term View Solid, Reimbursement a Woe – Nasdaq (nasdaq.com)
- Benzinga’s Top Upgrades, Downgrades For March 7, 2018 – Benzinga (benzinga.com)
Quest Diagnostics (NYSE DGX) traded up $2.35 on Friday, reaching $106.99. 1,027,865 shares of the company were exchanged, compared to its average volume of 1,190,000. The firm has a market cap of $14,840.00, a P/E ratio of 22.62, a PEG ratio of 1.88 and a beta of 0.68. Quest Diagnostics has a 12-month low of $90.10 and a 12-month high of $112.96. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.15 and a current ratio of 1.24.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 18th. Investors of record on Wednesday, April 4th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.87%. The ex-dividend date of this dividend is Tuesday, April 3rd. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.45. Quest Diagnostics’s dividend payout ratio is 38.05%.
A number of research analysts have issued reports on DGX shares. Jefferies Group set a $98.00 target price on shares of Quest Diagnostics and gave the company a “hold” rating in a report on Saturday, November 25th. Evercore ISI started coverage on shares of Quest Diagnostics in a report on Thursday, January 4th. They issued an “in-line” rating and a $103.00 target price on the stock. Canaccord Genuity restated a “buy” rating and issued a $110.00 target price on shares of Quest Diagnostics in a report on Tuesday, January 16th. Mizuho set a $113.00 target price on shares of Quest Diagnostics and gave the company a “buy” rating in a report on Wednesday, January 24th. Finally, Goldman Sachs Group began coverage on shares of Quest Diagnostics in a report on Monday, January 29th. They set a “buy” rating and a $117.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and nine have given a buy rating to the company’s stock. Quest Diagnostics currently has a consensus rating of “Hold” and an average target price of $108.10.
In related news, SVP Catherine T. Doherty sold 5,556 shares of the stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $101.00, for a total transaction of $561,156.00. Following the completion of the sale, the senior vice president now owns 78,890 shares of the company’s stock, valued at approximately $7,967,890. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP J. E. Davis sold 5,122 shares of the stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $101.00, for a total transaction of $517,322.00. Following the sale, the executive vice president now directly owns 48,909 shares of the company’s stock, valued at approximately $4,939,809. The disclosure for this sale can be found here. In the last three months, insiders have sold 208,358 shares of company stock valued at $21,617,807. Corporate insiders own 1.75% of the company’s stock.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.